Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment

Journal of Neurochemistry
M E AlburgesGlen R Hanson

Abstract

Methylphenidate (MPD) is a psychostimulant widely used to treat behavioral problems such as attention deficit hyperactivity disorder. MPD competitively inhibits the dopamine (DA) transporter. Previous studies demonstrated that stimulants of abuse, such as cocaine (COC) and methamphetamine differentially alter rat brain neurotensin (NT) systems through DA mechanisms. As NT is a neuropeptide primarily associated with the regulation of the nigrostriatal and mesolimbic DA systems, the effect of MPD on NT-like immunoreactivity (NTLI) content in several basal ganglia regions was assessed. MPD, at doses of 2.0 or 10.0 mg/kg, s.c., significantly increased the NTLI contents in dorsal striatum, substantia nigra and globus pallidus; similar increases in NTLI were observed in these areas after administration of COC (30.0 mg/kg, i.p.). No changes in NTLI occurred within the nucleus accumbens, frontal cortex and ventral tegmental area following MPD treatment. In addition, the NTLI changes in basal ganglia regions induced by MPD were prevented when D(1) (SCH 23390) or D(2) (eticlopride) receptor antagonists were coadministered with MPD. MPD treatment also increased dynorphin (DYN) levels in basal ganglia structures. These findings provide evi...Continue Reading

References

Nov 8, 2014·Behavioral Sciences·Paul FredricksonElliott Richelson
Feb 14, 2014·Psychopharmacology·M E AlburgesGlen R Hanson
Oct 23, 2012·Progress in Neurobiology·Heinz Steiner, Vincent Van Waes
Oct 9, 2012·Peptides·Richard J Bodnar
Apr 1, 2014·Journal of Neurochemistry·Christopher L GermanGlen R Hanson
Aug 27, 2014·Synapse·Christopher L GermanGlen R Hanson
Jun 24, 2015·Pharmacology, Biochemistry, and Behavior·Catherine M Claussen, Nachum Dafny
Jan 17, 2012·Neuroscience·Glen R HansonP S Frankel
Apr 6, 2019·Pharmacogenetics and Genomics·Tyler StevensTeri E Klein

Citations

Dec 15, 1976·Life Sciences·G R Uhl, S H Snyder
Jun 17, 1977·Brain Research·C B NemeroffM A Lipton
Feb 18, 1992·European Journal of Pharmacology·Pierre-Paul RompréA Gratton
Jul 18, 1989·European Journal of Pharmacology·Y L Hurd, U Ungerstedt
Jan 24, 1989·European Journal of Pharmacology·Glen R HansonJ W Gibb
Apr 1, 1985·Pharmacology, Biochemistry, and Behavior·D E HernandezA J Prange
Aug 9, 1988·European Journal of Pharmacology·K M MerchantGlen R Hanson
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 16, 1984·Brain Research·P W GlimcherB G Hoebel
Dec 13, 1993·Neuroreport·M N CastelT Hökfelt
Apr 1, 1994·The European Journal of Neuroscience·M N CastelT Hökfelt
Jun 1, 1995·Archives of General Psychiatry·Nora D VolkowR Hitzemann
Dec 5, 1994·Brain Research·J D WagstaffGlen R Hanson
Jan 1, 1993·Brain Research. Brain Research Reviews·P W Kalivas
Jul 1, 1993·Pharmacology, Biochemistry, and Behavior·C G McNamaraS Schenk
Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·J S LinM Jouvet
Jan 1, 1997·Life Sciences·O GaytanNachum Dafny
Jun 17, 1998·Molecular Neurobiology·R E Harlan, M M Garcia
Jul 22, 1998·The Journal of Clinical Psychiatry·Frances R LevinHerbert D Kleber
Mar 30, 1999·Brain Research. Molecular Brain Research·Glen R Hanson, K A Keefe
May 9, 2000·Journal of Neurochemistry·J M BrownAnnette E Fleckenstein
Mar 17, 2001·Nature Reviews. Neuroscience·E J Nestler
Aug 30, 2001·European Journal of Pharmacology·Mona BoulesElliott Richelson
Aug 7, 2002·European Journal of Pharmacology·Evan L RiddleAnnette E Fleckenstein
Jun 13, 2003·Life Sciences·Elliott RichelsonPaul Fredrickson
Sep 27, 2003·The European Journal of Neuroscience·Cindy L Brandon, Heinz Steiner
Jan 8, 2004·Journal of Clinical Psychopharmacology·Stephen V FaraoneJoseph Biederman
Jan 10, 2004·Journal of Neurochemistry·Ryuichi FukuiAkinori Nishi
Jan 8, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Motoyo Yano, Heinz Steiner
Oct 11, 2005·Drug and Alcohol Dependence·Stephanie L CollinsSuzette M Evans
Dec 2, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Walter AdrianiCarla Perrone-Capano
Jun 30, 2007·Pharmacology, Biochemistry, and Behavior·Panayotis K ThanosNora D Volkow
Oct 30, 2007·Trends in Pharmacological Sciences·Motoyo Yano, Heinz Steiner
Nov 23, 2007·Journal of Addictive Diseases·Stanislay I SvetlovMark S Gold
Jul 28, 2009·Current Drug Abuse Reviews·Kristin E Bogle, Bradley H Smith

Related Concepts

Adrenal Cortex Diseases
Immunoreactivity
Globus Pallidus
Neostriatum
SCH 23390
Neurotensin
Methamphetamine Measurement
Dorsal Striatum
Entire Basal Nuclei
Substantia Nigra Structure

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.